MaxCyte, Inc. (MXCT) Market Cap & Valuation Ratios
MaxCyte, Inc. (MXCT) has a market cap of $144.5M and a price-to-sales ratio of 4.7, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MXCTMaxCyte, Inc.Follow MXCT — free
—
Price chart with a free account
- Market cap
- 144.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| MXCT | 0.1 | — | 1.2 | — | — | -13% | -135% | -26% |
| CV | 0.3 | — | 24.5 | — | -8.0% | +11% | -217% | -737% |
| QSI | 0.3 | — | 121.3 | — | — | -53% | — | -62% |
| CLPT | 0.3 | — | 7.1 | — | -11.2% | +26% | -73% | -160% |
| TMCI | 0.3 | — | 1.4 | — | -9.0% | -4% | -26% | -42% |
| LAB | 0.2 | — | — | — | — | -5% | -113% | -36% |
| RXST | 0.2 | — | — | — | -13.0% | -4% | -36% | -23% |
| INGN | 0.2 | — | 0.2 | — | -5.1% | +3% | -9% | -34% |
| CATX | 0.2 | — | — | — | — | — | — | -49% |
| QTRX | 0.1 | — | 0.3 | — | — | +22% | -100% | -87% |
| LUNG | 0.1 | — | 0.7 | — | — | -3% | -53% | -179% |
| Median of these 10 | — | 1.4 | — | -9.0% | -3% | -63% | -55% |
; EV/Sales 1.2 vs. 1.4.
Growth vs. price
each dot a company · hover or tap for valuesMaxCyte, Inc. — questions
- What is MaxCyte, Inc.'s market cap?
- $144.5M.
- What is MaxCyte, Inc.'s price-to-sales ratio?
- 4.7.
Every figure on this page comes from MaxCyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.